12th Oct 2020 14:42
Destiny Pharma PLC - clinical stage biotechnology company based in Brighton - Recruiting patients undergoing open heart surgery in the US and Europe for its XF-73 phase 2b clinical study. The study will assess the microbiological effect of XF-73 nasal gel on Staphylococcus aureus nasal carriage in patients scheduled for open heart surgery. Has so far recruited 101 of the 125 patients targeted for the study. Subject to another slowdown in recruitment due to Covid-19, the recruitment for the study is due to complete before the end of 2020 with results in the first quarter of 2021.
CEO Neil Clark says: "We are very pleased to report that we have passed the one hundred patients mark in our lead clinical study testing XF-73 as a novel product preventing the incidence of post-surgical infections. This follows a protocol amendment with the FDA and promising interim safety data announced earlier in the year. We expect to complete recruitment before the end of the year and report results in early 2021 as we start preparations for the phase 3 study."
Current stock price: 75.00 pence
Year-to-date change: up 74%
By Anna Farley; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
DEST.L